Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDCK cell-based quadrivalent split influenza vaccine
- Development stage
- Phase 3
- Lead developer
- Wuhan Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MDCK cell-based quadrivalent split influenza vaccine is an inactivated, split-virion vaccine developed for the prevention of seasonal influenza. Unlike traditional influenza vaccines produced in embryonated chicken eggs, this vaccine is manufactured using Madin-Darby Canine Kidney (MDCK) cell culture technology. This cell-based platform avoids egg-adaptation mutations, ensures a more reliable supply chain during pandemics, and is suitable for individuals with egg allergies. The vaccine is quadrivalent, containing antigens from two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). It is developed by the Wuhan Institute of Biological Products in collaboration with Lanzhou Bailing Biotechnology and Northwest Minzu University, and has been evaluated in Phase III clinical trials in China for individuals aged 3 years and older.
- Other names
- MDCK-QIVquadrivalent influenza split vaccine (MDCK cells)四价流感病毒裂解疫苗（MDCK细胞）
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on MDCK cell-based quadrivalent split influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MDCK cell-based quadrivalent split influenza vaccine.